Sight Sciences has completed enrollment in the SAHARA trial, which is evaluating the TearCare system to treat the signs and symptoms of dry eye disease, according to a press release.
The multicenter, randomized controlled trial includes 310 participants and will compare the dry eye therapeutic device against 6 months of twice-daily Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan). Those in the TearCare group received an in-office eyelid debridement, a 15-minute thermal session with TearCare and physician-guided manual expression of the meibomian glands.
The primary endpoints of the